🇺🇸 FDA
Patent

US 7378108

Percutaneous absorption preparation of compound having angiotensin II antagonistic activity

granted A61KA61K31/4178A61K31/4245

Quick answer

US patent 7378108 (Percutaneous absorption preparation of compound having angiotensin II antagonistic activity) held by Takeda Pharmaceutical Company Limited expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 27 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/4178, A61K31/4245, A61K47/10, A61K47/14